FIGURE 6.

FOG2 participates in IL-6-induced hepatic insulin resistance. The levels of FOG2 protein were measured in the livers of db/db mice (A). The levels of FOG2 mRNA and protein were also analyzed in the NCTC 1469 cells treated with 10 ng/ml IL-6 for 24 h (B), the mouse primary hepatocytes exposed to 10 ng/ml IL-6 for 24 h (C), and the livers of mice injected with IL-6 for 7 days (D). Six siRNAs (si-676, si-1341, 3445, si-2530, si-2590, and si-3510) targeting FOG2 mRNA were transfected into the NCTC 1469 cells. The NCTC 1469 cells (negative control (NC)) were transfected with six siRNAs (si-676, si-1341, 3445, si-2530, si-2590, and si-3510) targeting FOG2 mRNA for 48 h followed by 10 ng/ml IL-6 treatment for 24 h. The FOG2 expression was determined by Western blots (E). The activation of the AKT/GSK pathway and the glycogen content (F and G) were analyzed in the NCTC 1469 cells transfected with si-3510-FOG2 and si-676-FOG2 for 48 h followed by 10 ng/ml IL-6 treatment for 24 h. The level of GSK phosphorylation and the content of glycogen (H) were measured in the NCTC1469 cells transfected with si-3510-FOG2 for 48 h, followed by treatment with 30 μm LY294002 for 24 h. Data represent the means ± S.E., n = 5 independent experiments in the db/db mice; n = 3 independent experiments in both NCTC 1469 cells and mouse primary hepatocytes; n = 4 independent experiments in the mice injected with IL-6. *, p < 0.05 versus control. p-AKT and p-GSK, phospho-AKT and -GSK, respectively.